文献速递银屑病与炎症性皮肤病

HLA-C*06:02状态与银屑病患者乌司奴单抗疗效差异的系统评价与荟萃分析

Association of HLA-C*06:02 Status With Differential Response to Ustekinumab in Patients With Psoriasis: A Systematic Review and Meta-analysis.
PubMed 文献 · JAMA Dermatol · 2019-01-01

该系统评价与荟萃分析纳入8项研究,评估HLA-C*06:02状态与乌司奴单抗治疗银屑病6个月后PASI75应答的关联。主要分析纳入937例患者,随机效应模型显示HLA-C*06:02阳性组PASI75风险差为0.24(95%CI 0.14-0.35;P<.001),阳性组汇总应答率89%,阴性组62%。结论认为虽存在疗效差异,但阴性组应答率也较高,不应据此排除治疗。

要点

  • HLA-C*06:02阳性患者乌司奴单抗6个月PASI75应答率高于阴性患者。
  • 阳性组汇总PASI75应答率89%,阴性组62%,风险差0.24。
  • 不应因HLA-C*06:02阴性而排除乌司奴单抗治疗。

核心结论

  • 荟萃分析显示银屑病患者HLA-C*06:02状态与乌司奴单抗疗效存在差异,阳性者PASI75应答更高。
  • 尽管阳性组应答率高,阴性组PASI75应答率也较高,无理由根据HLA-C*06:02阴性排除乌司奴单抗治疗。

研究设计与样本

  • 系统评价与荟萃分析,检索MEDLINE、Embase、Cochrane Library、Web of Science及灰色文献,时限2000年1月1日至2018年5月14日。
  • 纳入报告HLA-C*06:02状态与乌司奴单抗治疗斑块状银屑病3和/或6个月后PASI75应答关联的随机临床试验和观察性研究。
  • 共纳入8项研究,1048例患者进入荟萃分析,937例患者进入6个月PASI75应答的主要分析。

主要发现

  • 随机效应荟萃分析显示,6个月PASI75应答的风险差为0.24(95%CI 0.14-0.35;P<.001),有利于HLA-C*06:02阳性患者。
  • HLA-C*06:02阳性组PASI75应答率中位数92%(汇总89%;范围62%-98%)。
  • HLA-C*06:02阴性组PASI75应答率中位数67%(汇总62%;范围40%-84%)。
  • 异质性可能较大,I2为82%。

关键数值与推荐

  • 主要结局为乌司奴单抗治疗6个月后HLA-C*06:02阳性与阴性患者达到PASI75的风险差。
  • HLA-C*06:02阳性组汇总PASI75应答率89%,阴性组62%,风险差0.24(95%CI 0.14-0.35;P<.001)。

临床怎么用

  • 乌司奴单抗治疗银屑病时,HLA-C*06:02阳性患者可能获得更高PASI75应答,但阴性患者也有较高应答率。
  • 不应仅凭HLA-C*06:02阴性结果排除患者接受乌司奴单抗治疗。

局限性

  • 异质性可能较大,I2为82%。
  • 检索语言限制为英语、法语、德语和荷兰语。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Previous research showed a differential response to ustekinumab therapy based on HLA-C*06:02 status in patients with psoriasis but consisted mostly of small (and sometimes inconclusive) cohort studies. OBJECTIVE: To assess whether HLA-C*06:02 status is associated with a differential response to ustekinumab therapy in patients with psoriasis through a systematic review and a meta-analysis of available data. DATA SOURCES: A comprehensive search was conducted using MEDLINE, Embase, the Cochrane Library, Web of Science, and gray literature sources. Databases were searched from January 1, 2000, to May 14, 2018. Search strategies included terms and synonyms for psoriasis, HLA-C, and ustekinumab. Languages were restricted to English, French, German, and Dutch. STUDY SELECTION: Studies were included if they reported the association between HLA-C*06:02 status and 75% improvement in Psoriasis Area and Severity Index (PASI75) response to ustekinumab therapy in patients with plaque psoriasis after 6 and/or 3 months of treatment. Randomized clinical trials and observational studies were included. Screening and selection were performed independently by 2 reviewers. DATA EXTRACTION AND SYNTHESIS: HLA-C*06:02 genotype status and PASI75 response rates were extracted by 2 reviewers. Data were pooled using random-effects models. Heterogeneity was assessed using the τ2 and I2 statistic. Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) and Meta-Analysis of Observational Studies in Epidemiology (MOOSE) reporting guidelines were followed. MAIN OUTCOME AND MEASURE: The primary outcome was the risk difference of achieving PASI75 after 6 months of ustekinumab therapy between HLA-C*06:02-positive and HLA-C*06:02-negative patients. RESULTS: A total of 8 studies were reviewed; 1048 patients were included for meta-analyses, and 937 patients were included for the primary analysis of PASI75 response after 6 months of treatment. Random-effects meta-analysis showed a risk difference of 0.24 (95% CI, 0.14-0.35; P < .001) in favor of HLA-C*06:02-positive patients. The median PASI75 response rate in the HLA-C*06:02-positive group was 92% (pooled, 89%; range, 62%-98%). For HLA-C*06:02-negative patients, the median response rate was 67% (pooled, 62%; range, 40%-84%). Substantial heterogeneity may have been present, with an I2 of 82%. CONCLUSIONS AND RELEVANCE: The meta-analysis showed a differential response to ustekinumab therapy based on HLA-C*06:02 status in patients with psoriasis. Although HLA-C*06:02-positive patients had high PASI75 response rates after 6 months, the PASI75 response rate was also high in the HLA-C*06:02-negative group. There appears to be no rationale for excluding patients from ustekinumab treatment based on a negative HLA-C*06:02 status.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. van Vugt LJ, van den Reek JMPA, Hannink G, et al. Association of HLA-C*06:02 Status With Differential Response to Ustekinumab in Patients With Psoriasis: A Systematic Review and Meta-analysis. JAMA Dermatol. 2019. PMID: 30994858. doi:10.1001/jamadermatol.2019.0098

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。